BACKGROUND: Cardiovascular disease (CVD) risk prediction tools are often applied to populations beyond those in which they were designed when validated tools for specific subpopulations are unavailable. METHODS: Using data from 2283 human immunodeficiency virus (HIV)-infected adults aged ≥18 years, who were active in the HIV Outpatient Study (HOPS), we assessed performance of 3 commonly used CVD prediction models developed for general populations: Framingham general cardiovascular Risk Score (FRS), American College of Cardiology/American Heart Association Pooled Cohort equations (PCEs), and Systematic COronary Risk Evaluation (SCORE) high-risk equation, and 1 model developed in HIV-infected persons: the Data Collection on Adverse Effects of Anti-HIV Drugs (D:A:D) study equation. C-statistics assessed model discrimination and the ratio of expected to observed events (E/O) and Hosmer-Lemeshow χ2 P value assessed calibration. RESULTS: From January 2002 through September 2013, 195 (8.5%) HOPS participants experienced an incident CVD event in 15 056 person-years. The FRS demonstrated moderate discrimination and was well calibrated (C-statistic: 0.66, E/O: 1.01, P = .89). The PCE and D:A:D risk equations demonstrated good discrimination but were less well calibrated (C-statistics: 0.71 and 0.72 and E/O: 0.88 and 0.80, respectively; P < .001 for both), whereas SCORE performed poorly (C-statistic: 0.59, E/O: 1.72; P = .48). CONCLUSIONS: Only the FRS accurately estimated risk of CVD events, while PCE and D:A:D underestimated risk. Although these models could potentially be used to rank US HIV-infected individuals at higher or lower risk for CVD, the models may fail to identify substantial numbers of HIV-infected persons with elevated CVD risk who could potentially benefit from additional medical treatment. Published by Oxford University Press for the Infectious Diseases Society of America 2016. This work is written by (a) US Government employee(s) and is in the public domain in the US.
BACKGROUND:Cardiovascular disease (CVD) risk prediction tools are often applied to populations beyond those in which they were designed when validated tools for specific subpopulations are unavailable. METHODS: Using data from 2283 human immunodeficiency virus (HIV)-infected adults aged ≥18 years, who were active in the HIVOutpatient Study (HOPS), we assessed performance of 3 commonly used CVD prediction models developed for general populations: Framingham general cardiovascular Risk Score (FRS), American College of Cardiology/American Heart Association Pooled Cohort equations (PCEs), and Systematic COronary Risk Evaluation (SCORE) high-risk equation, and 1 model developed in HIV-infectedpersons: the Data Collection on Adverse Effects of Anti-HIV Drugs (D:A:D) study equation. C-statistics assessed model discrimination and the ratio of expected to observed events (E/O) and Hosmer-Lemeshow χ2 P value assessed calibration. RESULTS: From January 2002 through September 2013, 195 (8.5%) HOPSparticipants experienced an incident CVD event in 15 056 person-years. The FRS demonstrated moderate discrimination and was well calibrated (C-statistic: 0.66, E/O: 1.01, P = .89). The PCE and D:A:D risk equations demonstrated good discrimination but were less well calibrated (C-statistics: 0.71 and 0.72 and E/O: 0.88 and 0.80, respectively; P < .001 for both), whereas SCORE performed poorly (C-statistic: 0.59, E/O: 1.72; P = .48). CONCLUSIONS: Only the FRS accurately estimated risk of CVD events, while PCE and D:A:D underestimated risk. Although these models could potentially be used to rank US HIV-infected individuals at higher or lower risk for CVD, the models may fail to identify substantial numbers of HIV-infectedpersons with elevated CVD risk who could potentially benefit from additional medical treatment. Published by Oxford University Press for the Infectious Diseases Society of America 2016. This work is written by (a) US Government employee(s) and is in the public domain in the US.
Authors: Zeljko Reiner; Alberico L Catapano; Guy De Backer; Ian Graham; Marja-Riitta Taskinen; Olov Wiklund; Stefan Agewall; Eduardo Alegria; M John Chapman; Paul Durrington; Serap Erdine; Julian Halcox; Richard Hobbs; John Kjekshus; Pasquale Perrone Filardi; Gabriele Riccardi; Robert F Storey; David Wood Journal: Eur Heart J Date: 2011-06-28 Impact factor: 29.983
Authors: Matthew S Freiberg; Chung-Chou H Chang; Lewis H Kuller; Melissa Skanderson; Elliott Lowy; Kevin L Kraemer; Adeel A Butt; Matthew Bidwell Goetz; David Leaf; Kris Ann Oursler; David Rimland; Maria Rodriguez Barradas; Sheldon Brown; Cynthia Gibert; Kathy McGinnis; Kristina Crothers; Jason Sico; Heidi Crane; Alberta Warner; Stephen Gottlieb; John Gottdiener; Russell P Tracy; Matthew Budoff; Courtney Watson; Kaku A Armah; Donna Doebler; Kendall Bryant; Amy C Justice Journal: JAMA Intern Med Date: 2013-04-22 Impact factor: 21.873
Authors: Kate Buchacz; Rose K Baker; Anne C Moorman; James T Richardson; Kathleen C Wood; Scott D Holmberg; John T Brooks Journal: AIDS Date: 2008-07-11 Impact factor: 4.177
Authors: Hernando Knobel; Carlos Jericó; Milagro Montero; María L Sorli; Manuela Velat; Ana Guelar; Pere Saballs; Juan Pedro-Botet Journal: AIDS Patient Care STDS Date: 2007-07 Impact factor: 5.078
Authors: Michael J Silverberg; Wendy Leyden; Leo Hurley; Alan S Go; Charles P Quesenberry; Daniel Klein; Michael A Horberg Journal: Ann Intern Med Date: 2009-03-03 Impact factor: 25.391
Authors: Nwora Lance Okeke; Damian M Craig; Michael J Muehlbauer; Olga Ilkayeva; Meredith E Clement; Susanna Naggie; Svati H Shah Journal: Metabolomics Date: 2018-01-31 Impact factor: 4.290
Authors: Seamus P Whelton; Jennifer A Deal; Michelle Zikusoka; Lisa P Jacobson; Sudipa Sarkar; Frank J Palella; Lawrence Kingsley; Matthew Budoff; Mallory D Witt; Todd T Brown; Wendy S Post Journal: AIDS Date: 2019-05-01 Impact factor: 4.177
Authors: Mary Clare Masters; Karen M Krueger; Janna L Williams; Lindsay Morrison; Susan E Cohn Journal: Expert Rev Clin Pharmacol Date: 2019-12 Impact factor: 5.045
Authors: Raza M Alvi; Markella V Zanni; Anne M Neilan; Malek Z O Hassan; Noor Tariq; Lili Zhang; Maryam Afshar; Dahlia Banerji; Connor P Mulligan; Adam Rokicki; Magid Awadalla; James L Januzzi; Tomas G Neilan Journal: Clin Infect Dis Date: 2020-08-22 Impact factor: 9.079
Authors: Stephen K Williams; Brent A Johnson; Jonathan N Tobin; Amneris Esther Luque; Mechelle Sanders; Jennifer K Carroll; Andrea Cassells; Tameir Holder; Kevin Fiscella Journal: Prog Cardiovasc Dis Date: 2020-02-05 Impact factor: 8.194
Authors: Virginia A Triant; Jeremiah Perez; Susan Regan; Joseph M Massaro; James B Meigs; Steven K Grinspoon; Ralph B D'Agostino Journal: Circulation Date: 2018-02-14 Impact factor: 29.690
Authors: Nwora Lance Okeke; Allison R Webel; Hayden B Bosworth; Angela Aifah; Gerald S Bloomfield; Emily W Choi; Sarah Gonzales; Sarah Hale; Corrilynn O Hileman; Virginie Lopez-Kidwell; Charles Muiruri; Megan Oakes; Julie Schexnayder; Valerie Smith; Rajesh Vedanthan; Chris T Longenecker Journal: Am Heart J Date: 2019-07-18 Impact factor: 4.749